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MaBACKGROUND Cardiac magnetic resonance (CMR) is a component of the revised Task Force Criteria (rTFC) for the
diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). However, its diagnostic value in a pediatric
population is unknown.
OBJECTIVES This study examined the contribution of CMR to diagnosing ARVC using the rTFC in a pediatric population.
METHODS Clinical CMR studies of 142 pediatric patients evaluated for ARVC between 2005 and 2009 were reviewed.
Patients were categorized into “deﬁnitive,” “borderline,” “possible,” or “no” ARVC diagnostic groups based on the rTFC.
The extent to which each element of the rTFC contributed to diagnosing ARVC was determined using a c-statistics model.
RESULTS A total of 23 (16%), 32 (23%), 37 (26%), and 50 (35%) patients had deﬁnite, borderline, possible, and no
ARVC, respectively, applying the rTFC. The prevalence of regional wall motion abnormalities in these groups was 83%,
53%, 22%, and 16%, respectively (p < 0.001). By CMR, right ventricular end-diastolic volumes were 118  31 cc/m2,
108  22 cc/m2, 94  14 cc/m2, and 92  18 cc/m2, respectively (p < 0.001). Right ventricular fatty inﬁltration and
ﬁbrosis were detected in only 1 and 3 patients, respectively, all of whom had deﬁnitive ARVC. Of all rTFC major criteria,
CMR had the largest c-statistic decline (c ¼ 0.163). Eleven of the 23 patients (48%) with deﬁnite ARVC would not have
been in this group if CMR had not been performed.
CONCLUSIONS CMR parameters are important contributors to a diagnosis of ARVC in children, using the rTFC. Fatty
inﬁltration and myocardial ﬁbrosis provide limited value in children and adolescents. (J Am Coll Cardiol 2015;65:987–95)
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ABBR EV I A T I ON S
AND ACRONYMS
ARVC = arrhythmogenic right
ventricular cardiomyopathy
CMR = cardiac
magnetic resonance
ECG = electrocardiogram
EDVi = end-diastolic
volume index
EF = ejection fraction
LV = left ventricle/ventricular
RV = right ventricle/ventricular
rTFC = revised Task
Force Criteria
SDS = standard
deviation scores
WMA = wall motion
abnormality
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988United States, is used to diagnose ARVC in
today’s practice (7). The rTFC are a com-
posite score of structural, histological, elec-
trical, and genetic features of the disease,
yielding a diagnostic certainty of either
“no,” “possible,” “borderline,” or “deﬁnite”
ARVC. The most important difference be-
tween the original criteria and the rTFC lies
within a quantitative and more deﬁned
assessment of RV size and function (7).
Even with the rTFC, diagnosing ARVC in
pediatric patients remains challenging. In
addition to the recognized shortcomings of
the rTFC (8–10), children who are gene-
positive for ARVC may not exhibit all of the
disease’s phenotypic features until adult-
hood. Cardiac magnetic resonance (CMR)
evaluation to assess RV end-diastolic volumeindex (EDVi), ejection fraction (EF), and presence of
wall motion abnormalities (WMAs) is part of the rTFC
scoring system and has been shown to be a useful
noninvasive tool to diagnose ARVC in adults (11).
CMR has also been advocated for the detection
of ﬁbrofatty degeneration of myocardium in adults
(12–14).SEE PAGE 996Despite a postulated advantage of CMR in detect-
ing early stages of ARVC (15), its usefulness in diag-
nosing ARVC in the pediatric population has yet to be
determined. The aims of this study were to: 1) eval-
uate the prevalence of CMR ﬁndings in children
diagnosed with ARVC; and 2) assess the importance of
CMR and other components of the rTFC for the
diagnosis of ARVC.
METHODS
Following approval by the institutional research
ethics board, all CMR studies performed between 2005
and 2009 in pediatric patients referred for ﬁrst-time
evaluation of suspected ARVC at the authors’ institu-
tion were reanalyzed. At the time of referral, patients
also underwent echocardiography, electrocardiogram
(ECG), signal-averaged ECG, and 24-h Holter moni-
toring. Each diagnostic modality was analyzed in a
single laboratory at the authors’ institution, following
uniform protocols and reading criteria, although
not by a single reader. Echocardiographic studies
included parasternal long- and short-axis views
to assess regional WMAs and right ventricular out-
ﬂow tract (RVOT) diameter as well as an apical
4-chamber view for RV fractional area change.
Where available, results of endomyocardial biopsywere recorded. As all endomyocardial biopsies were
clinically graded prior to the revision of the Task
Force Criteria in 2010, it was not possible to differ-
entiate between major and minor histological
criteria. Consequently, the presence of qualitative
ﬁbrofatty inﬁltration as per the original Task Force
Criteria was included as a positive major criterion
for the purpose of this study (7).
CMR scanswere performed on a 1.5-T scanner (Signa
CV/I, General Electric Medical Systems, Milwaukee,
Wisconsin; or Avanto, Siemens Medical Solutions,
Erlangen, Germany). The CMR protocol included cine
imaging in axial, short-axis, and 2-chamber planes
using the steady-state free precession technique;
double inversion fast spin-echo acquisitions for
myocardial fat imaging; and late gadolinium en-
hancement for the detection of myocardial ﬁbrosis.
The cine short-axis stack was analyzed in the routine
clinical fashion to determine RV volumetric parame-
ters using commercially-available software (Mass
Analysis, Medis Medical Imaging Systems, Leiden, the
Netherlands).
All CMR studies were retrospectively reviewed for
presence and severity of WMAs, fatty inﬁltration, and
myocardial ﬁbrosis by an experienced reader (L.G-W.)
who was blinded to the results of other diagnostic
tests, including ventricular volumes, as well as to
the overall classiﬁcation according to the rTFC. The
locations of fatty inﬁltration, ﬁbrosis, and WMAs
were described using the RV 9-segment model, as
described by Wald et al. (16). Additional qualitative
CMR ﬁndings in the RV included the presence of an-
eurysms, wall thinning, accordion sign, outﬂow tract
dilation, abnormal trabeculations, and hypertrophy.
Patients with concomitant congenital heart disease
or no/insufﬁcient axial or short-axis cine imaging
were excluded. Further, patients lacking clinical data
in more than 2 of the rTFC criteria categories were
excluded.
STATISTICAL ANALYSIS. Demographic information
and test results of the study population are presented
either as means and SD or as frequencies, where
appropriate. Differences in prevalence of CMR ﬁnd-
ings among the 4 categories of ARVC diagnostic cer-
tainty were assessed by linear or logistic regression
using ARVC diagnosis as a categorical variable with
no ARVC as the reference category. A p value <0.05
was considered statistically signiﬁcant. To compare
EDVi and EF across ages and sexes, the values were
converted into standard deviation scores (SDS) as
per the lambda-mu-sigma method by relating indi-
vidual values for ventricular volumes and EFs to their
respective 50th percentiles (SDS ¼ 0) in age- and
TABLE 1 Revised Task Force Criteria for the Diagnosis of ARVC
Major Criteria Minor Criteria
I. Imaging
By 2D echo:
Regional RV akinesia, dyskinesia, or aneurysm
And 1 of the following (end diastole):
PLAX RVOT $32 mm (corrected for body size
[PLAX/BSA] $19 mm/m2)
PSAX RVOT ‡36 mm (corrected for body size
[PSAX/BSA] $21 mm/m2)
Fractional area change £33%
By CMR:
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
And 1 of the following:
Ratio of RV end-diastolic volume to BSA ‡110 ml/m2
(male) or ‡100 ml/m2 (female)
RV ejection fraction £40%
By 2D echo:
Regional RV akinesia or dyskinesia
And 1 of the following (end diastole):
PLAX RVOT ‡29 to <32 mm (corrected for body size
[PLAX/BSA] ‡16 to <19 mm/m2)
PSAX RVOT ‡32 to <36 mm (corrected for body size
[PSAX/BSA] ‡18 to <21 mm/m2)
Fractional area change >33% to £40%
By CMR:
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
And 1 of the following:
Ratio of RV end-diastolic volume to BSA ‡100 to <110 ml/m2 (male) or
‡90 to <100 ml/m2 (female)
RV ejection fraction >40% to £45%
By RV angiography:
Regional RV akinesia, dyskinesia, or aneurysm
II. Endomyocardial Biopsy
Residual myocytes (60% by morphometric analysis or 50% if estimated),
with ﬁbrous replacement of the RV free wall myocardium in $1 sample,
with or without fatty replacement of tissue on endomyocardial biopsy
Residual myocytes (60% to 75% by morphometric analysis or 50% to 65%
if estimated), with ﬁbrous replacement of the RV free wall
myocardium in ‡1 sample, with or without fatty replacement of tissue on
endomyocardial biopsy
III. Repolarization Abnormalities
Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in
individuals >14 years of age (in the absence of complete right
bundle-branch block QRS $120 ms)
Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the
absence of complete right bundle-branch block) or in V4, V5, or V6
Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of
age in the presence of complete right bundle-branch block
IV. Depolarization/Conduction Abnormalities
Epsilon wave (reproducible low-amplitude signals between end of QRS
complex to onset of the T-wave) in the right precordial leads (V1 to V3)
Late potentials by SAECG in $1 of 3 parameters in the absence of a QRS
duration of ‡110 ms on the standard ECG
Filtered QRS duration (fQRS) $114 ms
Duration of terminal QRS <40 mV (low-amplitude signal duration) $38 ms
Root mean square voltage of terminal 40 ms #20 mV
Terminal activation duration of QRS $55 ms measured from the nadir of
the S-wave to the end of the QRS, including R0, in V1, V2, or V3, in the
absence of complete right bundle-branch block
V. Arrhythmias
Nonsustained or sustained ventricular tachycardia of left bundle-branch
morphology with superior axis (negative or indeterminate QRS in
leads II, III, and aVF and positive in lead aVL)
Nonsustained or sustained ventricular tachycardia of RV outﬂow conﬁguration,
left bundle-branch block morphology with inferior axis (positive QRS in leads
II, III, and aVF and negative in lead aVL), or of unknown axis
>500 ventricular extrasystoles per 24 h (Holter)
VI. Family History
ARVC conﬁrmed in a ﬁrst-degree relative who meets current TFC
ARVC conﬁrmed pathologically at autopsy or surgery in a
ﬁrst-degree relative
Identiﬁcation of a pathogenic mutation categorized as associated
or probably associated with ARVC in the patient under evaluation
History of ARVC in a ﬁrst-degree relative in whom it is not possible or
practical to determine whether the family member meets current TFC
Premature sudden death (<35 years of age) due to suspected ARVC in a
ﬁrst-degree relative
ARVC conﬁrmed pathologically or by current TFC in a second-degree relative
2D ¼ 2-dimensional; ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; aVF ¼ augmented voltage unipolar left foot lead; aVL ¼ augmented voltage unipolar left arm lead; BSA ¼ body surface area;
CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; echo ¼ echocardiography; PLAX ¼ parasternal long-axis view; PSAX ¼ parasternal short-axis view; RV ¼ right ventricle/ventricular;
RVOT ¼ right ventricular outﬂow tract; SAECG ¼ signal averaged electrocardiogram; TFC ¼ Task Force Criteria.
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989sex-speciﬁc healthy control subjects (17). The inter-
pretation of SDS is similar to that of z scores. In
contrast to z scores, however, SDS generation does
not rely on normally distributed data and is regarded
as more accurate, particularly when relatively small
samples are examined. A detailed description of this
approach can be found elsewhere (18). To determine
the contribution of each rTFC major criterion to the
diagnosis of ARVC, the c-statistic was used. For thec-statistic model to be applicable, the 4 ARVC diag-
nostic categories were reduced to a dichotomous
variable: “yes” or “no” ARVC. Deﬁnite and borderline
diagnostic groups were considered to have ARVC,
whereas possible and no groups were considered to
not have ARVC. Each major diagnostic criterion was
entered into the regression as a dichotomous (yes/no)
variable. The model was run multiple times, each
time withholding a single diagnostic criterion. The
TABLE 2 Patient Demographics and Reasons for Referral
Unaffected
(n ¼ 50)
Possible
ARVC
(n ¼ 37)
Borderline
ARVC
(n ¼ 32)
Deﬁnite
ARVC
(n ¼ 23) p Value
Male 27 (54) 19 (51) 17 (53) 17 (74) 0.32
Age, yrs 10.9  4.1* 12.1  4.1 12.4  4.0 11.8  3.6 0.35
Family history of ARVC 18 (36) 19 (51) 16 (50) 14 (61) 0.20
Cardiac symptoms 23 (46) 14 (38) 12 (38) 6 (26) 0.44
Sudden cardiac arrest 2 (4) 1 (3) 0 (0) 0 (0) 0.55
Arrhythmia 18 (36) 14 (38) 10 (31) 7 (30) 0.91
Abnormal ECG 1 (2) 0 (0) 1 (3) 1 (4) 0.68
Abnormal echo 3 (6) 1 (3) 1 (3) 0 (0) 0.61
Values are n (%) or mean  SD. *n ¼ 49.
Abbreviations as in Table 1.
TABLE 3 Prevalence
Imaging
Major
Minor
Endomyocardial biopsy
Done
Major*
Repolarization abnorm
Major
Minor
Depolarization abnorm
Major
Minor
Arrhythmia
Major
Minor
Family history of ARVC
Major
Minor
Values are n (%). *Major c
rTFC ¼ revised Task Forc
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990relative contribution-to-model ﬁt of each rTFC major
criterion was determined by the difference between
the c-statistic for the overall model and the c-statistic
for the model without that particular criterion. This
approach is similar to a previously published report
on adult ARVC (3). The statistical signiﬁcance of the
difference between the area under the curve obtained
from the different models was assessed using the
DeLong method (19). The primary reader reassessed a
randomly selected sample of 20 CMR studies after an
interval of at least 6 weeks following the primary
reading, and a second reader (S.J.Y.) assessed the
same sample for interobserver variability. Interraterof Major and Minor rTFC Across ARVC Diagnostic Groups
Unaffected
(n ¼ 50)
Possible
ARVC
(n ¼ 37)
Borderline
ARVC
(n ¼ 32)
Deﬁnite
ARVC
(n ¼ 23) p Value
0 (0) 2 (5) 12 (38) 16 (70) <0.001
3 (6) 5 (14) 3 (9) 2 (9) 0.69
9 (18) 6 (16) 11 (34) 9 (39) 0.08
0 (0) 0 (0) 3 (9) 6 (26) <0.001
alities
0 (0) 0 (0) 0 (0) 0 (0)† —
1 (2) 4 (11) 4 (13) 1 (4) 0.22
alities
0 (0)‡ 2 (5) 1 (3)§ 6 (26) 0.001
13 (30)‡ 21 (57) 24 (77)§ 12 (52) 0.001
0 (0) 0 (0) 0 (0)§ 1 (5)† 0.14
7 (14) 11 (30) 7 (23)§ 8 (35) 0.17
0 (0) 7 (19) 12 (38) 11 (48) <0.001
9 (18) 11 (30) 2 (6) 5 (22) 0.10
riteria as per the original Task Force Criteria. †n ¼ 22. ‡n ¼ 44. §n ¼ 31.
e Criteria; other abbreviations as in Table 1.and intrarater reliability were assessed using kappa
statistics. All statistical analyses were performed us-
ing SAS version 9.3 (SAS Institute, Cary, North
Carolina).
RESULTS
CMR studies from 213 patients referred for ﬁrst-time
imaging evaluation for ARVC were reviewed. Rea-
sons for referral included family history in 100 pa-
tients (47%), cardiac symptoms in 81 (38%),
ventricular arrhythmias in 75 (35%), incidentally
discovered abnormal ECG ﬁndings in 4 (2%), and
incidental abnormal echocardiographic ﬁndings in
6 (3%). Twenty-eight CMR studies were excluded for
incomplete or poor quality short-axis or axial cine
imaging, 23 for concomitant congenital heart disease,
and 20 because the rTFC criteria in 3 or more cate-
gories were unavailable. Demographics and preva-
lence of rTFC ﬁndings in the remaining 142 study
subjects are shown in Tables 2 and 3. Eighty patients
(56%) were male and 62 (44%) were female. Their
mean age was 13.8  3.2 years, with no signiﬁcant
difference between diagnostic groups (p ¼ 0.35). Of
the 142 included patients, 50 (35%) had no ARVC, 37
(26%) possible ARVC, 32 (23%) borderline ARVC, and
23 (16%) deﬁnite ARVC. The distribution of the 4
categories did not differ when patients were stratiﬁed
by reasons for referral (Table 2). Thirty-ﬁve (26%)
subjects had undergone endomyocardial biopsy, with
a positive biopsy in 6 of 9 (67%) patients with deﬁnite
ARVC, 3 of 11 (27%) with borderline ARVC, and no
patients with possible or no ARVC. One-third of the
study population (44 subjects) had undergone genetic
testing for known pathogenic ARVC mutations. Of
those with genetic testing results, a pathogenic mu-
tation was found in 4 of 9 (44%) patients with
deﬁnitive, 3 of 13 (23%) with borderline, 1 of 20 (5%)
with possible, and 0 of 7 with no ARVC.
Regional WMAs were present in 19 of 23 (83%)
patients with deﬁnite ARVC, 17 of 32 (53%) with
borderline, 8 of 37 (22%) with possible, and 8 of 50
(16%) with no ARVC (p < 0.001) (Table 4). Of 52 pa-
tients with WMAs, 47 (90%) had disturbances in the
proximal RVOT (segments 2, 5, and/or 8, according to
the classiﬁcation by Wald et al. [16]), 47 (71%) in the
distal RVOT (segments 1, 4, and/or 7), and 26 (50%)
in the remote RV free wall (3, 6, and/or 9). A total of
40 of the 52 patients with WMAs had at least 2
affected segments, and 21 had WMAs in 3 or more
segments. RV EDVi was signiﬁcantly different among
ARVC diagnostic groups (p < 0.001), with larger
volumes in the groups with higher diagnostic cer-
tainty of ARVC. RV EF was lower in subjects with a
TABLE 4 rTFC CMR Parameters and SDS
Unaffected
(n ¼ 50)
Possible
ARVC
(n ¼ 37)
Borderline
ARVC
(n ¼ 32)
Deﬁnitive
ARVC
(n ¼ 23) p Value
RV wall motion abnormalities 8 (16) 8 (22) 17 (53) 19 (83) <0.001
RV end-diastolic volume index, cc/m2 92  18* 94  14 108  22† 118  31 <0.001
RV end-diastolic volume index SDS 0.75* 1.05 1.94† 2.48 <0.001
RV ejection fraction, % 52  7 51  6 50  5 45  10 0.07
RV ejection fraction SDS 2.54 2.63 2.75 3.37 0.32
Values are n (%) or mean  SD unless otherwise indicated. *n ¼ 48. †n ¼ 31.
SDS ¼ standard deviation scores; other abbreviations as in Tables 1 and 3.
TABLE 5 Parameters Not Included in the rTFC
Unaffected
ARVC
(n ¼ 50)
Possible
ARVC
(n ¼ 37)
Borderline
ARVC
(n ¼ 32)
Deﬁnitive
ARVC
(n ¼ 23) p Value
RV outﬂow tract dilation 4 (8) 4 (11)* 8 (25) 6 (26) 0.08
RV trabeculation 4 (8) 2 (6)* 2 (6) 8 (35) 0.002
Accordion sign 0 (0) 1 (3)* 3 (9) 10 (43) <0.001
RV wall thinning 1 (2) 0 (0)* 4 (13) 3 (13) 0.04
LV end-diastolic volume index, cc/m2 85  16† 87  12 95  20‡ 97  19 <0.001
LV end-diastolic volume index SDS 0.20† 0.47 0.83‡ 0.97 0.08
LV ejection fraction, % 60  6 60  5 60  6 58  8 0.98
LV ejection fraction SDS 0.99 1.15 0.94 1.08 0.92
Values are n (%) or mean  SD unless otherwise indicated. *n ¼ 36. †n ¼ 48. ‡n ¼ 31.
LV ¼ left ventricular; other abbreviations as in Tables 1 and 4.
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991deﬁnitive diagnosis of ARVC compared with the
other diagnostic groups, although this difference
failed to reach statistical signiﬁcance (p¼0.07). TheRV
EDVi SDS increased gradually and signiﬁcantly with
progression from no to deﬁnite ARVC (p < 0.001)
(Table 4).
RV fatty inﬁltration and myocardial ﬁbrosis were
detected in 1 and 3 patients, respectively, all of whom
had deﬁnite ARVC per the rTFC. Grossly abnormal
RV trabeculations, accordion sign, and RV wall
thinning varied signiﬁcantly across diagnostic groups
(p ¼ 0.002, p < 0.001, and p ¼ 0.04, respectively) and
were more prevalent in the diagnostic groups with
greater ARVC certainty (Table 5). Patients with
deﬁnite ARVC had signiﬁcantly larger left ventricles
(LVs) than those with borderline, possible, or no
ARVC (LV EDVi 97.2  19.1 cc/m2 vs. 95.0  19.9 cc/m2,
87.3  11.8 cc/m2, and 85.4  16.3 cc/m2, respectively;
p < 0.001). LV EDVi SDS correlated with RV EDVi SDS
(r ¼ 0.63; p < 0.0001), and LV EF SDS correlated with
RV EF SDS (r ¼ 0.36; p < 0.0001).
Intrarater and interrater variability for all qualita-
tive CMR parameters is summarized in Table 6. The
agreement for intrarater and interrater reliability was
good for RVOT dilation, RV trabeculation, accordion
sign, and RV wall thinning, and was moderate for
presence of WMAs (17,20).
CONTRIBUTION OF CMR FINDINGS TO THE OVERALL
PERFORMANCE OF THE rTFC. A c-statistics model
was used to evaluate the contribution of each major
criterion within the rTFC to the performance of the
overall score. Minor criteria were not evaluated,
either because they were not assessed (biopsies), had
a low prevalence (repolarization abnormalities),
were, relatively speaking, evenly distributed across
the 4 diagnostic certainty groups (this was the case
for CMR, family history, and arrhythmia), or because
of low speciﬁcity (as for depolarization abnormalities
and echocardiographic abnormalities). To differen-
tiate between contributions from CMR and echocar-
diography, these 2 tests were considered as separate
variables in this model. In this cohort, only 2 patients
met major criteria for echocardiography and none
met minor criteria.
With all major criteria included in the logistic
regression model, a c-statistic of 0.933 was achieved
(Central Illustration). The rTFC major criteria ranked
as follows, in order of descending c-statistic decline,
indicating decreasing contribution of the individual
criterion for the performance of the rTFC: abnormal
CMR (c ¼ 0.163  0.038; p < 0.001), positive family
history (c ¼ 0.121  0.031; p < 0.001), biopsy
(c ¼ 0.038  0.020; p ¼ 0.06), abnormaldepolarization (c ¼ 0.008  0.009; p ¼ 0.25), echo-
cardiographic ﬁndings (c ¼ 0.002  0.024; p ¼ 1.00),
abnormal repolarization (no change, c ¼ 0.000 
0.024; p ¼ 1.00), and presence of arrhythmia
(c ¼ þ0.002  0.024; p ¼ 1.00). In summary, echo-
cardiography, repolarization abnormalities, and
arrhythmia did not make signiﬁcant contributions to
the diagnosis of ARVC in this population. In contrast,
CMR, family history, biopsy, and depolarization ab-
normalities fully accounted for the performance of
the diagnostic model, with a combined c-statistic of
0.933  0.024, which was similar to the performance
of a diagnostic model including all parameters
(p ¼ 1.00). Almost one-half (48%) of the patients with
deﬁnitive ARVC (11 of 23) would have been in a group
with lower diagnostic certainty without taking into
account their CMR ﬁndings.
DISCUSSION
In the absence of a single conclusive test, the diag-
nosis of ARVC in children remains challenging,
especially early in the clinical course when structural,
TABLE 6 Interrater and Intrarater Reliability for
Qualitative CMR Parameters
Interrater (k) Intrarater (k)
RV outﬂow tract dilation 0.705 0.793
RV trabeculation 0.775 0.801
Accordion sign 0.690 0.711
RV wall thinning 0.669 0.706
RV wall motion abnormalities 0.404 0.574
Abbreviations as in Table 1.
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992functional, and electrical alterations in the RV may be
minimal. CMR has become a powerful diagnostic im-
aging modality for anatomical delineation, functional
analysis, and tissue characterization in congenital
and acquired heart disease, including adult ARVC
(12–14,21).
The prevalence of CMR ﬁndings in adult patients
with suspected ARVC has been described both in
the era of the original criteria and of the rTFC (10,22).
In contrast, limited information is available on the
prevalence of CMR ﬁndings in children (23,24). Only 1
previous publication systematically described the
prevalence of CMR abnormalities in children referred
for ARVC assessment, but it was beyond that study’s
scope to stratify subjects by whether or not they had
ARVC (25). To the best of our knowledge, this is the
ﬁrst study to detail the prevalence as well as the
extent of WMAs, RV dilation, and systolic dysfunc-
tion in a large pediatric population with ARVC status
elucidated by rTFC.
In adults with this condition, the RV is signiﬁcantly
larger compared with control subjects (7,26,27).
Because RV enlargement is part of the rTFC, this as-
sociation between RV size and diagnostic certainty is
to be expected; our results corroborate this observa-
tion in a pediatric cohort. After conversion of RV EDVi
values to SDS to eliminate sex- and age-related ﬂuc-
tuations, a disproportionate RV enlargement in the
groups with higher diagnostic certainty persisted.
Interestingly, whereas RV EF remained stable
across the ﬁrst 3 diagnostic groups, RV EDVi (absolute
and SDS) increased gradually with higher diagnostic
certainty for ARVC. Although this is a cross-sectional
study and any longitudinal conclusions from it
remain speculative, the discrepancy between earlier
RV enlargement and relatively late deterioration in
EF may suggest that pediatric ARVC patients have
relatively preserved global RV systolic function dur-
ing early stages of the disease, whereas RV enlarge-
ment begins early in the course.
Further, all 4 ARVC diagnostic groups contained
individuals with abnormal RV EF by SDS, includingthe unaffected ARVC group. There are several
possible reasons for this observation. Cutoffs for
normal RV EF may not be applicable to pediatric
populations. Alternatively, the unaffected and pos-
sible ARVC groups in this study may contain patients
who are not entirely “normal” and may develop more
signs of the condition at an older age. More impor-
tantly for the context of this study, however, is the
fact that as ARVC diagnostic certainty increases,
the RV EF SDS becomes more abnormal (Table 4).
Although regional WMAs are commonly found in
patients with ARVC (26–28), little is known about
exactly where in the RV these disturbances occur in
ARVC. In our cohort, most WMAs were located within
the RV outﬂow tract, a common origin of electrical
ventricular ectopy in ARVC. Whether this ﬁnding
represents a true predilection for this site or reﬂects
easier perception on imaging is unclear. The high
prevalence of WMAs, as well as the performance of
CMR in the c-statistics model, suggests that recogni-
tion of WMAs is important in securing an ARVC diag-
nosis. However, WMAs can be difﬁcult to assess in
clinical routine as reﬂected by only moderate intra-
rater and interrater reproducibility for WMAs in the
current study. New methods to quantify regional RV
contractility by CMR in a less user-dependent fashion
may prove useful in detecting and quantifying RV
WMAs more objectively and reproducibly (29).
ROLE OF CMR IN DIAGNOSING ARVC IN CHILDREN.
The current study suggests that CMR contributes
importantly to the diagnosis of ARVC in the setting of
early disease in a pediatric age group: CMR was
“needed” to achieve a diagnostic certainty of deﬁnite
in one-half of all patients in that category. Of all major
criteria within the rTFC, CMR made the greatest
contribution to the performance of the diagnostic
score. There was poor agreement of CMR ﬁndings (and
overall score) with echocardiographic ﬁndings of RV
dysfunction and enlargement, with only 2 patients in
the entire cohort meeting major echocardiographic
rTFC criteria and nonemeetingminor criteria. In many
conditions, echocardiography and CMR correlate well,
but in the presence of pathology the agreement be-
tween the 2 modalities is typically weaker than in
healthy control subjects (18). Furthermore, the 2 mo-
dalities tend to correlate best for continuous variables
(20,30). The rTFC are based on categorical variables
(presence or absence of WMAs) or dichotomized
continuous variables (cutoffs for RVOT diameter or
fractional area change). In this situation, agreement
between echocardiography and CMR becomes much
less reliable, especially when different measurements
are compared (RVOT diameter and fractional area
CENTRAL ILLUSTRATION Diagnosing ARVC in Children and Adolescents: Contributions of
Major rTFC to ARVC Diagnosis
The revised Task Force Criteria (rTFC) are used to diagnose arrhythmogenic right ventricular cardiomyopathy (ARVC), and this study looked at
how each individual criterion affects the overall performance of the score in a pediatric population. As seen here via the attributable effects in
the c-statistic, removal of cardiac magnetic resonance (CMR) reduces diagnostic performance the most, whereas echocardiographic (Echo) and
electrocardiographic abnormalities and presence of arrhythmias are of lesser signiﬁcance.
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993change by echocardiography vs. RV volume and RV EF
by CMR).
A study by Marcus et al. (3) revealed echocardiog-
raphy as the most important criterion in the frame-
work of the original Task Force Criteria for adults. In
their study, CMR contributed only marginally to the
overall score. This discrepancy in comparison with
our results may stem from 2 differences between the 2
studies. First, Marcus et al. (3) used the original Task
Force Criteria; in the current study, participants were
evaluated according to the revised TFC. Second, RV
regional dysfunction and dilation are likely more
subtle in children and adolescents than in adults.
Echocardiography may be insensitive to these early
changes of ARVC due to limitations in acoustic win-
dows to the RV free wall as compared with CMR.
Consequently, as anticipated by Basso et al. (15) in
their 2009 review paper, CMR may prove to be a
more suitable tool than echocardiography in the
detection of early functional and anatomical signs of
the condition. In contrast, the abnormalities in adults
may be sufﬁciently pronounced to be detected via
echocardiography.Another reason why CMR has been advocated in
ARVC is that it has a unique ability to noninvasively
detect ﬁbrosis and fatty inﬁltration of the RV in pa-
tients with suspected ARVC, although fat and ﬁbrosis
detection by noninvasive imaging is not part of the
rTFC (21,31). However, in clinical practice, the un-
equivocal detection of fatty inﬁltration of the RV by
CMR is often challenging (32). In our cohort, only 1
patient had convincing evidence of fatty inﬁltration.
This patient, alongwith 2 others, also hadﬁbrosis of the
RV myocardium. All 3 had deﬁnite ARVC and also had
other imaging ﬁndings, including WMAs, dilated RVs,
and reduced RV EF. Given the paucity of convincing
ﬁbrofatty inﬁltration in our cohort and the fact that it
was always associated with other imaging abnormal-
ities, we believe that fat-sensitive sequences and late
gadolinium enhancement carry low incremental yields
in pediatric patients with suspected ARVC.
Besides ﬁbrofatty inﬁltration of the myocardium,
other structural changes have been identiﬁed in
patients with ARVC, including focal RV wall thinning,
abnormal RV trabecular architecture, and the so-
called “accordion sign” (33). In our cohort, all of
PERSPECTIVES
COMPETENCY IN PATIENT CARE: The diagnostic
evaluation of pediatric patients with suspected ARVC
generally relies upon the European Society of Car-
diology’s 2010 rTFC, which address the structural,
histological, electrical, and genetic features of the
disease. The family medical history and results of
CMR imaging are particularly important factors to
consider.
TRANSLATIONAL OUTLOOK: Further studies are
needed to elucidate the diagnostic and prognostic
signiﬁcance of LV involvement in patients with signs
and symptoms of ARVC, particularly as these evolve
though childhood and adolescence.
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ducibility on intrarater assessment (k between 0.669
and 0.775) and inter-rater assessment (k between
0.706 and 0.801) and differed signiﬁcantly across
groups of diagnostic certainty. The magnitude of the
kappa coefﬁcient for each qualitative CMR parameter
was lower than expected, likely given the small
sample size. Nonetheless, these abnormalities should
be reported if present.
Traditionally, and reﬂected by its name, ARVC has
been regarded as a disease primarily of the RV. More
recently, Asimaki et al. (34) elegantly showed that the
same desmosomal changes that cause myocyte loss
and electrical instability in the RV are also present in
the interventricular septum and in the LV. On a
macroscopic level, regional LV dysfunction is not
uncommon in patients with ARVC (35). Interestingly,
patients in our cohort who had deﬁnite or borderline
ARVC had larger LVs than those with possible or no
ARVC. Further, RV enlargement and dysfunction also
was associated with LV enlargement and dysfunction.
Whether LV changes in these patients occur inde-
pendently of RV pathology or result from ventricular
interaction in the presence of predominantly right-
sided disease remains to be clariﬁed.
Interestingly, a mutation associated with ARVC
was identiﬁed in less than one-half of the patients
with deﬁnite ARVC who underwent genetic testing.
The most likely explanation is that there are yet un-
detected or untested genes responsible for ARVC
diagnosis or that patients are so labeled but, in re-
ality, have a different condition.
STUDY LIMITATIONS. The absence of an independent
diagnostic gold standard made it impossible to
calculate speciﬁcity and sensitivity for the individual
components of the rTFC. Instead, like Marcus et al. (3)
before us, we used a c-statistics model to assess the
diagnostic performance of each rTFC parameter.
Nevertheless, the fact that the ultimate diagnostic
group of no to deﬁnite ARVC depends on the variables
whose diagnostic merits are being evaluated remains
a strong confounder. Although this limits our current
study, it cannot be avoided and is at the root of an
imperfect clinical diagnostic tool to this day (3). There
was a paucity of patients in our study cohort who
underwent endomyocardial biopsy. In most centers,
including ours, children and adolescents undergo
biopsy more selectively than adults. Last, althoughthe rTFC do not include “hypokinesia” as a positive
WMA criterion, we believe that akinesia and hypo-
kinesia represent a spectrum of regional disturbances
of contractility. The distinction can be difﬁcult and is,
in fact, arbitrary. Given that most children are ex-
pected to be in early stages of ARVC, a decision was
made to include hypokinesia as a positive WMA
ﬁnding before analysis was begun.
CONCLUSIONS
CMR ﬁndings are frequent in children and adoles-
cents with a suspicion for ARVC. CMR parameters
listed in the rTFC, including RV EDVi and WMAs, are
important contributors to diagnosing ARVC in this
age group. Although widely measured, fatty inﬁltra-
tion and myocardial ﬁbrosis rarely occur in children
and offer little incremental value during a CMR ex-
amination. LV enlargement and systolic dysfunction,
on the other hand, are common and can provide
important clues to the diagnosis. Our study suggests
that CMR is more useful as a diagnostic imaging mo-
dality than echocardiography for ARVC diagnosis in
the context of the rTFC.
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